As assessed by flow cytometry, we also found that the levels of pSTAT5 are higher in putative MPN-SC in patients with JAK2 V617F+ MPN compared to patients with JAK2 V617F− MPN or normal CD34+/CD38− stem cells. Here, JAK2 is linked to myeloproliferative disorder.